SCHEMBL1471348

SCHEMBL1471348

CC1CN(Cc2ccc(OC(F)(F)F)cc2)CC(C)N1S(=O)(=O)c1ccc2scc(CC(=O)O)c2c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGDR2 Q9Y5Y4 4/20 0.40
TEAD1 P28347 1/20 0.40
KEAP1 Q14145 1/20 0.39
NFE2L2 Q16236 1/20 0.39
PPARD Q03181 5/20 0.39
PPARG P37231 4/20 0.39
PPARA Q07869 4/20 0.39
CHRM4 P08173 1/20 0.37
SCN7A Q01118 1/20 0.37
SCN5A Q14524 1/20 0.37
DRD2 P14416 1/20 0.36
DRD4 P21917 1/20 0.36
CHRM2 P08172 2/20 0.36
CHRM5 P08912 1/20 0.36
CHRM1 P11229 1/20 0.36
CHRM3 P20309 1/20 0.36
PDE1B Q01064 1/20 0.35
AKR1C3 P42330 1/20 0.35
SERPINE1 P05121 1/20 0.35
ALDH1A1 P00352 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1471347 1.00 PTGDR2 (0.40) PTGDR2TEAD1KEAP1NFE2L2PPARD
SCHEMBL1470796 0.89 PPARD (0.48) PTGDR2KEAP1NFE2L2PPARDPPARG
SCHEMBL1470799 0.89 PPARD (0.48) PTGDR2KEAP1NFE2L2PPARDPPARG
SCHEMBL13034732 0.87 KEAP1 (0.43) PTGDR2KEAP1NFE2L2
SCHEMBL13804972 0.85 PTGDR2 (0.42) PTGDR2TEAD1PPARDCHRM4SCN7A
SCHEMBL4212887 0.85 PTGDR2 (0.42) PTGDR2TEAD1PPARDCHRM4SCN7A
SCHEMBL13804985 0.81 PPARD (0.44) PTGDR2TEAD1PPARDCHRM4DRD2
SCHEMBL4212951 0.81 PPARD (0.44) PTGDR2TEAD1PPARDCHRM4DRD2
SCHEMBL13804984 0.79 TEAD1 (0.42) PTGDR2TEAD1PPARDPPARGPPARA
SCHEMBL4221461 0.79 TEAD1 (0.42) PTGDR2TEAD1PPARDPPARGPPARA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1805158-B1 SULFONYL-SUBSTITUTED BICYCLIC COMPOUNDS AS MODULATORS OF PPAR KALYPSYS INC (US) 2018-06-27 EP disclosed
US-7915253-B2 4-[2,6-Dimethyl-4-(4-trifluoromethoxy-phenyl)-piperazine-1-sulfonyl]-indan-2-carboxylic acid; peroxisome proliferator activated receptors modulator; antidiabetic, antiinflammatory agent; obesity, hyperinsulinemia, metabolic syndrome X, polycystic ovary syndrome, ischemia-associated organ injury KALYPSYS, INC (US) 2011-03-29 US disclosed
US-7834004-B2 Sulfonyl-substituted bicyclic compounds as modulators of PPAR KALYPSYS, INC (US) 2010-11-16 US disclosed
US-20090264417-A1 SULFONYL-SUBSTITUTED BICYCLIC COMPOUNDS AS MODULATORS OF PPAR KALYPSYS, INC. (US) 2009-10-22 US disclosed
US-20090227599-A1 SULFONYL-SUBSTITUTED BICYCLIC COMPOUNDS AS MODULATORS OF PPAR KALYPSYS, INC. (US) 2009-09-10 US disclosed
US-7517884-B2 {5-[4-(4-Trifluoromethyl-phenyl)-piperazine-1-sulfonyl]-indan-2-yl}-acetic acid; peroxisome proliferator activated receptors modulator; antidiabetic, antiinflammatory agent; obesity, hyperinsulinemia, metabolic syndrome X, polycystic ovary syndrome, ischemia-associated organ injury, diabetes KALYPSYS INC. (US) 2009-04-14 US disclosed
US-7494999-B2 Sulfonyl-substituted bicyclic compounds as modulators of PPAR KALYPSYS, INC (US) 2009-02-24 US disclosed
US-20090029971-A1 SULFONYL-SUBSTITUTED BICYCLIC COMPOUNDS AS MODULATORS OF PPAR KALYPSYS, INC. (US) 2009-01-29 US disclosed
US-20060205736-A1 Sulfonyl-substituted bicyclic compounds as modulators of PPAR KALYPSYS, INC. 2006-09-14 US disclosed
US-20060167012-A1 Sulfonyl-substituted bicyclic compounds as modulators of PPAR KALYPSYS, INC. 2006-07-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060167012-A1 Sulfonyl-substituted bicyclic compounds as modulators of PPAR PPARG, PPARA, PPARD PTGDR2 182/4885TEAD1 3032/4885KEAP1 3203/4885
US-20090029971-A1 SULFONYL-SUBSTITUTED BICYCLIC COMPOUNDS AS MODULATORS OF PPAR PPARG, PPARA, PPARD PTGDR2 182/4885TEAD1 3032/4885KEAP1 3203/4885
US-20090227599-A1 SULFONYL-SUBSTITUTED BICYCLIC COMPOUNDS AS MODULATORS OF PPAR PPARG, PPARA, PPARD PTGDR2 182/4885TEAD1 3032/4885KEAP1 3203/4885
US-20060205736-A1 Sulfonyl-substituted bicyclic compounds as modulators of PPAR PPARG, PPARA, PPARD PTGDR2 182/4885TEAD1 3032/4885KEAP1 3203/4885
US-20090264417-A1 SULFONYL-SUBSTITUTED BICYCLIC COMPOUNDS AS MODULATORS OF PPAR PPARG, PPARA, PPARD PTGDR2 182/4885TEAD1 3032/4885KEAP1 3203/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.